Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (≥65 years) patients in the CRUCIAL trial

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 453-463

  Kim, Jae Hyung ^a   Zamorano, José ^b   Erdine, Serap ^c   Pavia, Abel ^d   Al Khadra, Ayman ^e   Sutradhar, Santosh ^f   Yunis, Carla ^f  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c ISTANBUL UNIVERSITY   (Turkey)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e PRINCE SULTAN CARDIAC CENTER   (Saudi Arabia)

^f PFIZER INC   (United States)

Author keywords

Age; Cardiovascular risk; Hypertension; Lipid lowering therapy

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; AMLODIPINE; CORONARY DISEASE; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84876216748     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.781503     Document Type: Article

References (40)

1. Arnold AM, Psaty BM, Kuller LH, et al. Incidence of cardiovascular disease in older Americans: the cardiovascular health study. J Am Geriatr Soc 2005;53:211-18
2. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
5. Strategic Priorities. WHO. Available at: www.who.int/cardiovascular- diseases/priorities/en [Last accessed 23 May 2012]
6. Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007;21:297-309
7. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-9
8. Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
9. Bahler C, Gutzwiller F, Erne P, et al. Lower age at first myocardial infarction in female compared to male smokers. Eur J Prev Cardiol 2011;19:1184-93
10. Ulmer H, Kelleher C, Diem G, et al. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: The Vorarlberg Health Monitoring & Promotion Programme. Eur Heart J 2003;24:1004-13
11. General Lifestyle Overview: A report on the 2010 General Lifestyle Survey. Office for National Statistics. Available at: www.ons.gov.uk [Last accessed 2 October 2012]
12. Jackson R, Chambless L, Higgins M, et al. Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors 1997;7:43-54
13. McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64:256-63
14. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204-8
15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
16. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3
17. Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583-91
18. Collier DJ, Poulter NR, Dahlof B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA). J Hypertens 2011;29:592-9
19. Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercholesterolemia. Curr Med Res Opin 2010;26:439-43
20. Zamorano J, Erdine S, Lopez AP, et al. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010;122:7-15
21. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011;27: 821-33
22. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005;7:264-73
23. Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009;23:196-210
24. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008;83:35-45
25. Hobbs FD, Gensini G, Mancini GB, et al. An international open-label program to assess the efficacy of single-pill amlodipine/atorvastatin in attaining recommended BP and lipid levels: The JEWEL Programme. Eur J Cardiovasc Prev Rehabil 2009;16:472-80
26. Feldman R, Flack J, Howes L, et al. Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Curr Med Res Opin 2012;28:1421-33
27. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120: 713-19
28. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium- channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010;10:29
29. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
30. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med J Aust 2011;195:134-7
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
32. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
33. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
34. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421
35. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged565 versus 65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study. Am J Cardiol 2009;103: 577-82
36. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007;5:52-63
37. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106: 1024-8
38. FDA Drug Safety Communication: important safety label changes to cholesterol- lowering statin drugs. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm [Last accessed 12 March 2013]
39. Hey-Hadavi JH, Kuntze E, Luo D, et al. Tolerability of atorvastatin in a population aged 65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. Am J Geriatr Pharmacother 2006;4:112-22
40. Medical Research Council. MRC Cluster Randomized Trials: Methodological and Ethical Considerations. London: MRC, 2002